Thus, we examined the effect of exogenous TGFβ treatment on TAGLN expression, as well as on the expression of a number of TGFβ-responsive genes (ACTA2, and TPM1), in the RKO colon cancer cell model. The gene discussed is TAGLN; the disease is malignant colon neoplasm.